Routine C-suite departure with standard severance — no immediate read-through for operations or strategy. Monitor for naming of a successor Chief Commercial Officer and any broader management changes.
Price Chart
Executive Summary
Myriad Genetics filed an 8-K reporting the separation of Chief Commercial Officer Brian Donnelly, effective September 21, 2026, and the entry into a Separation Agreement. Donnelly will receive a lump sum severance payment of $1,322,294 plus accelerated equity vesting on time-based awards scheduled to vest within two years. The departure was previously disclosed and is a routine C-suite separation with standard severance terms — no red flags such as termination for cause or unexpected resignation are indicated.
Key Facts
- Chief Commercial Officer Brian Donnelly separated from Myriad Genetics effective September 21, 2026.
- Donnelly receives a lump sum severance payment of $1,322,294.
- Time-based equity awards scheduled to vest within two years of the Separation Date will be accelerated to vest on the Separation Date.
- Performance-based equity awards remain outstanding and may vest if conditions are met within two years.
- The separation was previously disclosed on September 16, 2026 — this filing formalizes the Separation Agreement.
- No replacement for the Chief Commercial Officer role is named in this filing.
Financial Impact
Severance payment of $1,322,294 plus accelerated equity vesting — immaterial relative to Myriad Genetics' market cap.
Risk Factors
- No successor named — prolonged vacancy in commercial leadership could impact sales execution.
- Accelerated equity vesting adds modest dilution over the next two years.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0000899923-26-000084 |
| Document: mygn-20261006.htm | 0000899923-26-000084 |
| Document: 0000899923-26-000084-index-headers.html | 0000899923-26-000084 |
| Document: 0000899923-26-000084-index.html | 0000899923-26-000084 |
| Document: 0000899923-26-000084.txt | 0000899923-26-000084 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $6.02 | awaiting T+1 | — | $6.29 (+4.49%) |
Oct 20, 2026 7d ago | 8-K | $5.54 $5.57 | ▲ +0.54% | ▲ +0.02% | $6.29 (+13.54%) |
Oct 15, 2026 12d ago | Press Release | $3.98 | awaiting T+1 | — | $6.29 (+58.04%) |
Oct 9, 2026 18d ago | 8-K | $4.20 $4.08 | ▼ −2.86% | ▼ −2.85% | $6.29 (+49.76%) |
Sep 16, 2026 5w ago | 8-K | $3.86 $4.14 | ▲ +7.25% | ▲ +6.12% | $6.29 (+62.95%) |
Sep 16, 2026 5w ago | Press Release | $3.86 $4.14 | ▲ +7.25% | ▲ +6.12% | $6.29 (+62.95%) |
Jul 30, 2026 12w ago | Press Release | $2.86 $3.02 | ▼ −5.59% | ▼ −4.17% | $6.29 (−119.93%) |
May 27, 2026 21w ago | Press Release | $3.93 $4.22 | ▲ +7.38% | ▲ +6.83% | $6.29 (+60.05%) |
Mar 17, 2026 32w ago | Press Release | $4.64 $4.75 | ▲ +2.37% | ▲ +2.64% | $6.29 (+35.56%) |
Feb 28, 2026 34w ago | Institutional Cluster | $5.01 $5.29 | ▲ +5.59% | ▲ +6.50% | $6.29 (+25.55%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers